Neurology® Podcast

1) Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. William Powers about his paper on lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Dr. Roy Strowd is reading our e-Pearl of the week about Déjà vu. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Doug Turnbull about the management of mitochondrial disorders. The participants had nothing to disclose except Drs. Southerland, Powers and Strowd.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Powers serves as an editorial board member of Stroke and Journal of Cerebral Blood Flow and Metabolism; serves on the scientific advisory board for Ontario Brain Institute Morehouse School of Medicine; receives research support from the NIH and UNC.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Benjamin Friedman about his paper on intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine. Dr. Roy Strowd is reading our e-Pearl of the week about evaluating the exome. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Robert Taylor about the investigations for mitochondrial disorders. The participants had nothing to disclose except Drs. Friedman and Strowd.Dr. Friedman serves on the scientific advisory board for MAP Pharmaceuticals.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Submandibular gland needle biopsy for diagnosis of Parkinson disease and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Brown interviews Dr. Charles Adler about his paper on submandibular gland needle biopsy for diagnosis of Parkinson disease. Dr. Roy Strowd is reading our e-Pearl of the week about nodes needing neurofascin. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Andrew Schaefer about syndromes of mitochondrial disorders. The participants had nothing to disclose except Drs. Adler and Strowd.Dr. Adler serves on the scientific advisory board of Bachmann Strauss Dystonia and Parkinson Foundation; is a consultant for Allergan, Inc., Novartis, Merz Pharmaceuticals, LLC, XenoPort, Inc.; receives royalties from the publication of the book Parkinson's Disease and Movement Disorders; receives research support from Avid Radiopharmaceuticals, Department of Defense, Michael J. Fox Foundation for Parkinson's Disease Research, National Parkinson's Foundation and NIH.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Clinical characteristics and outcome of brain abscess and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Cupka interviews Dr. Matthijs Brouwer about his paper on clinical characteristics and outcome of brain abscess. Dr. Roy Strowd is reading our e-Pearl of the week about angioedema after tPA. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Grainne Gorman about the fundamental principles of mitochondrial disorders. The participants had nothing to disclose except Drs. Brouwer, Strowd and Gorman.Dr. Brouwer receives research support from the Dutch Scientific Organization; received research support from the European Federation of Neurological Sciences and European Society of Clinical Microbiology and Infectious Diseases.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gorman receives research support from the UK NIHR Biomedical Research Centre for Aging and Age-related disease, Research Fellow, awarded to the Newcastle upon Tyne Trust Foundation Hospitals NHS Trust.

Interviews from the 2013 AAN Annual Meeting

1) Guideline on prevention of stroke in nonvalvular atrial fibrillation. and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Gary Gronseth about AAN paper on prevention of stroke in nonvalvular atrial fibrillation. Dr. James Addington is reading our e-Pearl of the week about superficial siderosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about Edoxaban, non-pharmaceutical options for stroke prevention in afib: ablation, atrial appendage occluder devices and any other options. The participants had nothing to disclose except Drs. Kissela, Gronseth, Addington, Southerland and Chaturvedi.Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring and provides medico-legal reviews.Dr. Gronseth serves as Associate Editor for for Neurology®; serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Clinical specificities of patients with NMDA receptor antibodies encephalitis and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Jerome Honnorat about his paper on the clinical specificities of patients with NMDA receptor antibodies encephalitis. Dr. James Addington is reading our e-Pearl of the week about posterior interosseous nerve syndrome. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Apixaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Addington and Chaturvedi.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Guillain-Barre syndrome being associated with hepatitis E virus infection and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barre syndrome being associated with hepatitis E virus infection. Dr. James Addington is reading our e-Pearl of the week about myelin-oligodendrocyte glycoprotein antibody. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Rivaroxaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Burns, Jacobs, Addington and Chaturvedi.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Jacobs serves as an editorial board member for Journal of the Peripheral Nerve System; received funding for travel from Baxter International Inc. for a scientific meeting; received research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) ASA/clopidogrel combination confers better long term vascular protection in ASA failure and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Robert Cote about his paper on whether the combination of ASA/clopidogrel confers better long term vascular protection in ASA failure. Dr. James Addington is reading our e-Pearl of the week about hypoglycorrhachia. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Dabigatran), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Cote, Addington, Southerland and Chaturvedi.Dr. Cote served on the scientific advisory board for Bayer Schering Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer Inc; serves on the scientific advisory board for DSMB for National Institute of Health (Point Study), Steering committee for the National Institute of Health (SPS3 study); is a consultant for Otsuka Pharmaceutical Co., Ltd.; received speaker honoraria from Boehringer Ingelheim, Merck Serono, Sanofi-aventis.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

Interviews with Bill Seely on frontotemporal dementia. Clinical presentations & bedside evaluation, diagnostic testing & genetics, therapeutics & future directions.